NO20052276L - Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi - Google Patents

Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi

Info

Publication number
NO20052276L
NO20052276L NO20052276A NO20052276A NO20052276L NO 20052276 L NO20052276 L NO 20052276L NO 20052276 A NO20052276 A NO 20052276A NO 20052276 A NO20052276 A NO 20052276A NO 20052276 L NO20052276 L NO 20052276L
Authority
NO
Norway
Prior art keywords
gene therapy
dna molecule
circulated
preparation
replication origin
Prior art date
Application number
NO20052276A
Other languages
English (en)
Other versions
NO20052276D0 (no
NO333932B1 (no
Inventor
Fabienne Soubrier
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of NO20052276D0 publication Critical patent/NO20052276D0/no
Publication of NO20052276L publication Critical patent/NO20052276L/no
Publication of NO333932B1 publication Critical patent/NO333932B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

En prokaryot rekombinant vertscelle omfattende et heterologt replikasjonsinitieringsprotein som aktiverer et kondisjonalt replikasjonsorigo og et ekstrakromosomalt DNA-molekyl omfattende et heterologt terapeutisk gen og et kondisjonelt replikasjonsorigo der funksjonaliteten i den prokaryote rekombinant vertscelle krever et replikasjonsinitieringsprotein som er fremmed for vertscellen beskrives. Vertscellen kan omfatte et pir-gen med minst en mutasjon, som kan opptre i pir-genkopikontrollområdet, pir-genets gli-delåsliknende leucin motiv eller pir-genets DNA-bindende region.
NO20052276A 2002-10-11 2005-05-10 Sirkulært DNA-molekyl med betinget replikasjonsorigo samt fremgangsmåte for dets fremstilling. NO333932B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/268,948 US7279313B2 (en) 1995-09-15 2002-10-11 Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
PCT/US2003/032512 WO2004033664A2 (en) 2002-10-11 2003-10-14 Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy

Publications (3)

Publication Number Publication Date
NO20052276D0 NO20052276D0 (no) 2005-05-10
NO20052276L true NO20052276L (no) 2005-07-06
NO333932B1 NO333932B1 (no) 2013-10-21

Family

ID=32092417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052276A NO333932B1 (no) 2002-10-11 2005-05-10 Sirkulært DNA-molekyl med betinget replikasjonsorigo samt fremgangsmåte for dets fremstilling.

Country Status (22)

Country Link
US (3) US7279313B2 (no)
EP (1) EP1549735B1 (no)
JP (2) JP4522861B2 (no)
KR (1) KR101323542B1 (no)
CN (2) CN100491521C (no)
AT (1) ATE521695T1 (no)
AU (2) AU2003287078B2 (no)
BR (1) BR0314512A (no)
CA (1) CA2501851C (no)
CY (1) CY1112110T1 (no)
DK (1) DK1549735T3 (no)
ES (1) ES2372599T3 (no)
HK (1) HK1082761B (no)
IL (1) IL167706A (no)
MX (1) MXPA05003857A (no)
NO (1) NO333932B1 (no)
NZ (2) NZ539311A (no)
PT (1) PT1549735E (no)
RU (1) RU2307870C2 (no)
SI (1) SI1549735T1 (no)
WO (1) WO2004033664A2 (no)
ZA (1) ZA200503039B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) * 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
EP2246413A3 (en) 2004-04-19 2011-10-26 Centelion Method for purifying plasmid DNA having pharmaceutical quality
RU2306338C2 (ru) * 2004-06-24 2007-09-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Mob'-ПРОИЗВОДНАЯ ПЛАЗМИДА RSF1010, НЕ СОДЕРЖАЩАЯ ГЕНЫ УСТОЙЧИВОСТИ К АНТИБИОТИКАМ, БАКТЕРИЯ, СОДЕРЖАЩАЯ УКАЗАННУЮ ПЛАЗМИДУ, И СПОСОБ ПОЛУЧЕНИЯ ПОЛЕЗНЫХ МЕТАБОЛИТОВ
JP4581851B2 (ja) * 2004-07-27 2010-11-17 セイコーエプソン株式会社 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器
FR2920158B1 (fr) * 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
EP2221066A1 (en) 2009-02-18 2010-08-25 Sanofi-Aventis Use of VgII3 activity modulator for the modulation of adipogenesis
EP2471909A1 (en) * 2010-12-30 2012-07-04 SIRION BIOTECH GmbH Nucleic acid molecules for generating adenoviral vectors
JP5863338B2 (ja) * 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
CA2883227A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
CN107002069A (zh) * 2014-11-18 2017-08-01 国立研究开发法人科学技术振兴机构 环状dna的扩增方法
JP7014721B2 (ja) 2015-09-18 2022-02-01 ディーエヌエーアールエックス インビボでの核酸発現のためのシステム及び方法
IL259842B (en) * 2015-12-11 2022-08-01 California Inst Of Techn Targeted peptides for the targeting of adeno-associated viruses -aavs-
WO2018175932A1 (en) * 2017-03-23 2018-09-27 DNARx Systems and methods for nucleic acid expression in vivo
DK3768846T5 (da) 2018-03-21 2024-08-19 Aldevron L L C Virale og ikke-virale nanoplasmidvektorer med forbedret produktion
US20210277385A1 (en) * 2018-07-30 2021-09-09 OriCiro Genomics, Inc. Method for editing dna in cell-free system
WO2020148652A1 (en) * 2019-01-18 2020-07-23 Janssen Biotech, Inc. β-GALACTOSIDASE ALPHA PEPTIDE AS A NON-ANTIBIOTIC SELECTION MARKER AND USES THEREOF
EP4034662A1 (en) * 2019-09-25 2022-08-03 Katholieke Universiteit Leuven, K.U.Leuven R&D Large vectors and methods for high-yield production
US20250011798A1 (en) * 2021-10-18 2025-01-09 Modernatx, Inc. Markerless dna production
US20250354159A1 (en) * 2022-06-13 2025-11-20 Nanjing GenScript Biotech Co., Ltd. Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025208072A1 (en) * 2024-03-29 2025-10-02 The General Hospital Corporation Methods and materials for treating disorders related to bacterial infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4654307A (en) * 1983-02-17 1987-03-31 The Research Foundation Of State University Of New York Novel bacteria containing a plasmid having a tRNA code
US4761367A (en) * 1984-11-07 1988-08-02 The University Of North Carolina At Chapel Hill Vectors suitable for detection of eukaryotic DNA regulatory sequences
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US5510099A (en) * 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
RU2107725C1 (ru) * 1989-02-24 1998-03-27 Монсанто Компани Способ модификации фрагмента днк, кодирующего инсектицидный белок bacillus thuringiensis, фрагмент днк, кодирующий инсектицидный белок bacillus thuringiensis (варианты), фрагмент днк, содержащий структурный ген, кодирующий инсектицидный белок (варианты), и фрагмент днк, содержащий структурный ген, кодирующий слитый белок
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5512463A (en) * 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
TW201794B (no) * 1991-05-03 1993-03-11 American Cyanamid Co
US5714323A (en) * 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
US5444149A (en) * 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
JP4098355B2 (ja) * 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
WO1996001899A1 (en) 1994-07-08 1996-01-25 Schering Corporation METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS
DE4428402A1 (de) 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5792647A (en) * 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
JP3530676B2 (ja) * 1995-04-26 2004-05-24 キヤノン株式会社 光受容部材の製造方法、該光受容部材、該光受容部材を有する電子写真装置及び該光受容部材を用いた電子写真プロセス
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US5874259A (en) 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector
WO2004108167A1 (en) 2003-06-05 2004-12-16 Gencell Sas Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Also Published As

Publication number Publication date
US7279313B2 (en) 2007-10-09
EP1549735A2 (en) 2005-07-06
CN100491521C (zh) 2009-05-27
DK1549735T3 (da) 2011-12-12
MXPA05003857A (es) 2005-06-22
NZ539311A (en) 2008-06-30
HK1086297A1 (zh) 2006-09-15
NZ566205A (en) 2009-02-28
US20070015282A1 (en) 2007-01-18
US20090252713A1 (en) 2009-10-08
IL167706A (en) 2012-05-31
WO2004033664A3 (en) 2004-12-29
CA2501851C (en) 2014-03-11
SI1549735T1 (sl) 2011-12-30
EP1549735A4 (en) 2006-05-03
CA2501851A1 (en) 2004-04-22
JP2006502714A (ja) 2006-01-26
HK1082761A1 (en) 2006-06-16
JP2010057493A (ja) 2010-03-18
AU2009201405A1 (en) 2009-05-07
US7807444B2 (en) 2010-10-05
US20030161844A1 (en) 2003-08-28
AU2003287078B2 (en) 2009-01-15
US20070141708A2 (en) 2007-06-21
PT1549735E (pt) 2011-11-30
CN1717476A (zh) 2006-01-04
WO2004033664A2 (en) 2004-04-22
NO20052276D0 (no) 2005-05-10
NO333932B1 (no) 2013-10-21
JP4522861B2 (ja) 2010-08-11
KR101323542B1 (ko) 2013-10-29
HK1082761B (en) 2012-05-18
JP4750203B2 (ja) 2011-08-17
RU2005114367A (ru) 2005-12-20
CN101182534A (zh) 2008-05-21
AU2003287078A1 (en) 2004-05-04
KR20050084847A (ko) 2005-08-29
ZA200503039B (en) 2006-11-29
BR0314512A (pt) 2005-07-26
CY1112110T1 (el) 2015-11-04
ATE521695T1 (de) 2011-09-15
CN101182534B (zh) 2013-04-24
ES2372599T3 (es) 2012-01-24
EP1549735B1 (en) 2011-08-24
RU2307870C2 (ru) 2007-10-10

Similar Documents

Publication Publication Date Title
NO20052276L (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
BRPI0814781A8 (pt) ''proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico descarboxilase''
NO20081233L (no) Albumin fusjonsproteiner
WO2019139645A3 (en) High efficiency base editors comprising gam
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
NO20064059L (no) Albumin fusjonsproteiner
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
AR048025A1 (es) Plantas con actividad aumentada de una enzima fosforilante del almidon
DK1781782T3 (da) Modificerede vitamin K-afhængige polypeptider
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
AR050299A1 (es) Plantas con una enzima fosforilante del almidon con una actividad aumentada en plástidos.
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
MA29075B1 (fr) Enzymes et procedes
DK1945762T3 (da) Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
WO2004053137A3 (en) Method for protein production
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
BRPI0512798A (pt) molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse
ATE488591T1 (de) Neuer l-lysin-induzierbarer promotor
Liu et al. Mutational switching of a yeast tRNA synthetase into a mammalian-like synthetase cytokine
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
AU2002346803A1 (en) Genes encoding for carbon metabolism and energy-producing proteins

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees